
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is well positioned to capitalize on the high unmet need for effective therapies targeting STAT3. Its pipeline includes two oral, small molecule drugs with promising early results and improved tolerability. With enough funding to continue operations until late 2026, the company is expected to drive value for its shareholders by advancing its innovative drug candidates through clinical trials.
Bears say
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies to target STAT3 for the treatment of inflammatory and proliferative diseases. While Tvardi's pipeline drugs, TTI-101 and TTI-109, show some promise in early clinical data, Tvardi faces significant risks, including competition in the HCC market, potential financing issues, and the structural limitations of targeting the SH2 domain of STAT3. These factors, combined with a negative market perception following a recent trial miss, lead to our cautious outlook on the company's stock.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares